{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T05:26:38Z","timestamp":1785907598996,"version":"3.56.0"},"reference-count":26,"publisher":"SAGE Publications","issue":"1","license":[{"start":{"date-parts":[[2021,5,10]],"date-time":"2021-05-10T00:00:00Z","timestamp":1620604800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Mult Scler"],"published-print":{"date-parts":[[2022,1]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>In the CLARITY (CLAdRIbine Tablets treating multiple sclerosis orallY) study of patients with relapsing-remitting multiple sclerosis, treatment with cladribine tablets 3.5\u2009mg\/kg (CladT) significantly reduced the annualised relapse rate (ARR) versus placebo; this effect was sustained in CLARITY Extension, without further treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>To assess the frequency and severity of relapses in patients treated with CladT versus placebo in CLARITY over 2\u2009years and evaluate the durability of effect in patients who received no further treatment for 2\u2009years in CLARITY Extension.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>In this post hoc analysis, ARRs were calculated for qualifying and all relapses, and qualifying and all severe relapses (i.e. requiring steroid treatment or leading to hospitalisation) in patients treated with CladT ( n\u2009=\u2009433) and placebo ( n\u2009=\u2009437) in CLARITY, and those from the CladT group who received placebo in CLARITY Extension ( n\u2009=\u200998).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>At Month 6, Year 1 and Year 2, patients receiving CladT had a significantly lower risk of qualifying or all relapses (all p\u2009&lt;\u20090.0001), and qualifying or all severe relapses (all p\u2009&lt;\u20090.005), compared with placebo. This effect was sustained in CLARITY Extension without further treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>The results show durable efficacy of cladribine tablets 3.5\u2009mg\/kg for reducing frequency and severity of relapses in patients with relapsing-remitting multiple sclerosis. CLARITY: NCT00213135; CLARITY Extension: NCT00641537<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/13524585211010294","type":"journal-article","created":{"date-parts":[[2021,5,10]],"date-time":"2021-05-10T05:46:14Z","timestamp":1620625574000},"page":"111-120","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":32,"title":["Analysis of frequency and severity of relapses in multiple sclerosis patients treated with cladribine tablets or placebo: The CLARITY and CLARITY Extension studies"],"prefix":"10.1177","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4930-7639","authenticated-orcid":false,"given":"Nicola","family":"De Stefano","sequence":"first","affiliation":[{"name":"Department of Neurological and Behavioural Sciences, University of Siena, Siena, Italy\/Department of Medicine, Surgery and Neuroscience, University of Siena, Siena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6892-104X","authenticated-orcid":false,"given":"Maria Pia","family":"Sormani","sequence":"additional","affiliation":[{"name":"Department of Health Sciences, University of Genoa and Ospedale Policlinico San Martino IRCCS, Genoa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gavin","family":"Giovannoni","sequence":"additional","affiliation":[{"name":"Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kottil","family":"Rammohan","sequence":"additional","affiliation":[{"name":"Department of Neurology, University of Miami School of Medicine, MS Research Center, Miami, FL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Leist","sequence":"additional","affiliation":[{"name":"Division of Clinical Neuroimmunology, Jefferson University, Comprehensive MS Center, Philadelphia, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia K","family":"Coyle","sequence":"additional","affiliation":[{"name":"Department of Neurology, Stony Brook University, Stony Brook, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"Dangond","sequence":"additional","affiliation":[{"name":"EMD Serono Research & Development Institute, Inc., Billerica, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Birgit","family":"Keller","sequence":"additional","affiliation":[{"name":"Merck KGaA, Darmstadt, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nektaria","family":"Alexandri","sequence":"additional","affiliation":[{"name":"Merck KGaA, Darmstadt, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Galazka","sequence":"additional","affiliation":[{"name":"Merck KGaA, Darmstadt, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2021,5,10]]},"reference":[{"key":"bibr1-13524585211010294","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(17)30470-2"},{"key":"bibr2-13524585211010294","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2019.04.017"},{"key":"bibr3-13524585211010294","doi-asserted-by":"publisher","DOI":"10.1212\/01.WNL.0000096175.39831.21"},{"key":"bibr4-13524585211010294","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3181c1e44f"},{"key":"bibr5-13524585211010294","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2007.01.063"},{"key":"bibr6-13524585211010294","doi-asserted-by":"publisher","DOI":"10.2165\/11592160-000000000-00000"},{"key":"bibr7-13524585211010294","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2015.09.011"},{"key":"bibr8-13524585211010294","doi-asserted-by":"publisher","DOI":"10.1177\/1352458510397221"},{"key":"bibr9-13524585211010294","doi-asserted-by":"publisher","DOI":"10.4178\/epih.e2017008"},{"key":"bibr10-13524585211010294","unstructured":"Merck Europe B.V. MAVENCLAD 10 mg summary of product characteristics, www.ema.europa.eu (2021, accessed 1 March 2021)."},{"key":"bibr11-13524585211010294","unstructured":"Merck Serono Inc. MAVENCLAD 10 mg FDA approved label, www.fda.gov (2019, accessed 12 August 2019)."},{"key":"bibr12-13524585211010294","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0902533"},{"key":"bibr13-13524585211010294","doi-asserted-by":"publisher","DOI":"10.1177\/1352458517727603"},{"key":"bibr14-13524585211010294","doi-asserted-by":"publisher","DOI":"10.1177\/1352458510391344"},{"key":"bibr15-13524585211010294","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2020.102572"},{"key":"bibr16-13524585211010294","first-page":"S249","volume":"15","author":"Vermersch P","year":"2009","journal-title":"Mult Scler J"},{"key":"bibr17-13524585211010294","doi-asserted-by":"publisher","DOI":"10.1177\/1756286419826547"},{"key":"bibr18-13524585211010294","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0050347"},{"key":"bibr19-13524585211010294","doi-asserted-by":"publisher","DOI":"10.1007\/s11940-015-0345-6"},{"key":"bibr20-13524585211010294","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.58.2.169"},{"key":"bibr21-13524585211010294","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1331.2005.01352.x"},{"key":"bibr22-13524585211010294","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2016.02.012"},{"key":"bibr23-13524585211010294","doi-asserted-by":"publisher","DOI":"10.1177\/1352458517726380"},{"key":"bibr24-13524585211010294","unstructured":"Novartis Pharmaceuticals Corporation. NDA 22527 medical review(s): GILENYA capsules, https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2010\/022527Orig1s000medr.pdf (2010, accessed 24 April 2020)."},{"key":"bibr25-13524585211010294","unstructured":"Biogen Inc. NDA 204063 medical review(s): TECFIDERA delayed-release capsules, https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2012\/202992Orig1s000MedR.pdf (2014, accessed 24 April 2020)."},{"key":"bibr26-13524585211010294","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1177\/1352458520974938","volume":"26","author":"Comi G","year":"2020","journal-title":"Mult Scler J"}],"container-title":["Multiple Sclerosis Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/13524585211010294","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/13524585211010294","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/13524585211010294","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T04:06:20Z","timestamp":1777694780000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/13524585211010294"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,10]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["10.1177\/13524585211010294"],"URL":"https:\/\/doi.org\/10.1177\/13524585211010294","relation":{},"ISSN":["1352-4585","1477-0970"],"issn-type":[{"value":"1352-4585","type":"print"},{"value":"1477-0970","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,10]]}}}